However, in view of the high price of anti-VEGF inhibitors and they often need to be used repeatedly, which is a great economic burden for both patients and society; patients tend to have poor compliance; and half of the patients do not respond to intravitreal injection of VEGF inhibitors [12], whereas steroid hormone therapy can increase the incidence of cataract and glaucoma. Here, VEGFA is linked to glaucoma.